Strides Pharma Science Limited (Strides) today announced the successful completion of the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYÉI), Hungary at its Puducherry facility on April 28, 2021. The Company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection. The company in August 2020 had also announced successful completion of the UK MHRA inspection at the site. The Puducherry facility caters to the U.S., Other Regulated Markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats.
Commenting on the development, Dr. R. Ananthanarayanan, Managing Director & CEO, remarked “We are pleased with the positive outcome of the recent EU GMP inspection at our Puducherry facility. The positive result of this inspection underscores our commitment to regulatory excellence at our global manufacturing sites. We stay focused on getting the facility reclassified with the USFDA”